• Langley Road, Brighton, MA
  • 416-402-8274

NIH Licensing Opportunity: Diagnostic to Manage Benign vs. Malignant Adrenal Tumors with 100% Negative Predictive Certainty


  • Start Date:November 03, 2017
  • End Date: November 03, 2017
  • Start Time:11:00 EST
  • End Time:12:00 EST
  • Location:WebEx
  • Email:
  • Register

Signature Square OMSIH logo

NIH Licensing Opportunity:
Diagnostic to Manage Benign vs. Malignant Adrenal Tumors with 100% Negative Predictive Certainty


One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.

Join us for this webinar that will introduce a ground-breaking diagnostic that allows physicians and surgeons to manage benign versus malignant adrenal tumors with 100% negative predictive certainty.

In the 80 million CT scans that are performed annually in the United States, up to 1.6 million times the ordering physician accidentally finds what could be an adrenal tumor. The question is, of course, is the tumor malignant or benign?

This new diagnostic will allow the patient and their physician or surgeon to avoid the current diagnostic options. This is important because current diagnostic testing is not always accurate. As well, many patients opt for surgery as the diagnostic evaluation to ensure the tumor is not malignant. This surgery can be unnecessary, and also unreliable, as the current pathology evaluation is often not definitive.

Dr. Kebebew has developed three (3) biomarker-based methods that accurately and reproducibly predict which adrenal tumors are not malignant, with 100% negative predictive certainty.

This is an opportunity to LICENSE THIS TECHNOLOGY, or participate in further collaborative work to enhance its development. Currently, among the three biomarker-based diagnostic tests, there are options for testing for adrenal cancer in urine, blood and tissue.

A separate, but distinct use for this BIO-MARKER BASED diagnostic test is also as a COMPANION DIAGNOSTIC.

If an oncologist wants to identify if a particular therapeutic treatment is working, the effectiveness of any therapeutic treatment can be assessed by determining the biomarker concentrations. Consequently, with this diagnostic biomarker-based test, a patient’s progress can be monitored by re-testing on a period basis, e.g., annually or bi-annually.

The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.

This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.

Dr. Electron Kebebew
Senior Investigator
National Cancer Institute
Center for Cancer Research (CCR)
Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™